Olanzapina: Guideline Summary for On-Label and Off-Label Use

Indications and Dosage

The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend olanzapina as an antiemetic for chemotherapy-induced nausea and vomiting (CINV) with a Category 1 recommendation 3, 4, 5
For acute agitation associated with schizophrenia or bipolar mania, the dosage is 2.5-10 mg IM, with alternative doses of 2.5 mg, 5 mg, 7.5 mg, or 10 mg IM based on clinical factors 1, 2
The NCCN recommends a 4-drug regimen including olanzapina 10 mg orally once before high-emetic-risk chemotherapy (HEC), then daily for 3 days, in combination with an NK1 antagonist, a 5-HT3 antagonist, and dexamethasone 3, 4, 5

Common side effects include fatigue, somnolence, and sleep disturbances 3, 4
Elderly patients should use olanzapina with caution, considering a reduced dose of 5 mg in elderly or excessively sedated patients 3, 4
A boxed warning from the FDA exists for death in patients with dementia-related psychosis; precautions should be taken for diabetes type II and hyperglycemia 3, 4
Pharmacological interactions should be avoided, including excessive dopaminergic blockade when used with metoclopramide, phenothiazines, or haloperidol 3, 4

Patients with hepatic insufficiency should start with a reduced dose of 2.5 mg 1, 2
Patients with Alzheimer's disease should start with a dose of 2.5 mg and consider the boxed warning from the FDA for dementia-related psychosis 1, 2, 3, 4

Essential monitoring includes long-term metabolic effects, such as weight, glucose, and lipids 2
Orthostatic hypotension, particularly with IM administration, should be monitored 2
Sedation and somnolence require continuous monitoring 2
Combination with benzodiazepines should be used with extreme caution due to the risk of hypersedation, respiratory depression, and reported fatalities 1, 2